Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 2/20 | 0.34 |
| ▸ | FPR3 | P25089 | 7/20 | 0.34 |
| ▸ | FPR2 | P25090 | 7/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654509 | 1.00 | GCK (0.38) | GCKSMN1; SMN2MAPK10CCNE1CDK2 | |
| SCHEMBL5381844 | 0.88 | GCK (0.41) | GCKSMN1; SMN2FFAR2 | |
| SCHEMBL2655251 | 0.88 | GCK (0.41) | GCKSMN1; SMN2FFAR2 | |
| SCHEMBL2653358 | 0.84 | GCK (0.55) | GCKSMN1; SMN2MAPTNPC1LMNA | |
| SCHEMBL2653353 | 0.84 | GCK (0.55) | GCKSMN1; SMN2MAPTNPC1LMNA | |
| SCHEMBL2655715 | 0.83 | GCK (0.46) | GCKSMN1; SMN2MAPK10CCNE1CDK2 | |
| SCHEMBL2655711 | 0.83 | GCK (0.46) | GCKSMN1; SMN2MAPK10CCNE1CDK2 | |
| SCHEMBL2646460 | 0.81 | GCK (0.59) | GCKFBP1 | |
| SCHEMBL2646462 | 0.81 | GCK (0.59) | GCKFBP1 | |
| SCHEMBL2645561 | 0.80 | GCK (0.58) | GCKFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262196-B2 | Tri(cyclo) substituted amide glucokinase activator compounds | PROSIDION LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
| EP-1594863-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004072066-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | GCKR, GCK, GALK1 | GCK 2/4885SMN1; SMN2 3707/4885MAPK10 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.